Starting in December 2021, our COVend researchers submitted to both their Competent Authority and Ethics Committee in different countries to jump start COVend’s clinical study IXION. As a result of their commitment to COVend, the first submissions were carried out by our German partners at the Goethe University Frankfurt am Main and at the University Hospital Würzburg. The first country submissions in Germany were closely followed by the Hospital Universitari de Bellvitge, the Hospital of Lithuanian University of Health Science Kaunas Clinics and Assistance Publique Hopitaux de Paris.

The submissions to the National Competent Authorities and Local Ethics Committee are the first step towards delivering our new promising therapy. Treating COVID patients suffering from the infection during mild and moderate stages is now one step closer.

Congratulations to our partners on their hard work and great teamwork!